Rockville-based CBMG Holdings announced Monday that following the spinoff of its stem cell business division, it has changed its name to AbelZeta Pharma Inc., which will focus on immune cell business.
The spinoff, approved by the company’s board of directors and shareholders, allows AbelZeta to focus greater resources on the development of immune cell therapy for cancer and inflammation and immunology diseases.
The company currently has 13 ongoing clinical studies in its immune cell pipeline in the United States and in China.